Changes in coactivators and corepressors, such as upregulation of FKBP51 and steroid receptor coactivators (SRC-1, SRC-2, SRC-3), also contribute to mCRPC progression, with SRC-3 overexpression linked to poorly differentiated, advanced prostate cancer [79]. The gene discussed is NCOA3; the disease is prostate carcinoma.